FINWIRES · TerminalLIVE
FINWIRES

Salubris Pharma's Clinical Trial Application for Lipid-Lowering Drug Accepted in China

By

Shenzhen Salubris Pharmaceuticals (SHE:002294) said China's drug regulator accepted its clinical trial application for SAL0195.

The drug targets lipid-related diseases, according to a Friday filing with the Shenzhen bourse.

Shares of the pharmaceutical company were down 2% in recent trade.

Related Articles